[
    [
        {
            "time": "",
            "original_text": "沃森生物 研发资本化率超高",
            "features": {
                "keywords": [
                    "沃森生物",
                    "研发",
                    "资本化率"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "沃森生物 研发资本化率超高",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "为何服务收入大幅下降？沃森生物收年报问询函 盈利能力下降",
            "features": {
                "keywords": [
                    "沃森生物",
                    "服务收入",
                    "盈利能力",
                    "年报",
                    "问询函"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "为何服务收入大幅下降？沃森生物收年报问询函 盈利能力下降",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "国产“疫苗之王”沃森生物奇葩事情多：第一二大股东魔术退位之争或从深交所11问中找到答案",
            "features": {
                "keywords": [
                    "沃森生物",
                    "疫苗",
                    "大股东",
                    "深交所",
                    "问询"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 0,
                "Sentiment": 0,
                "Importance": 0,
                "Impact": 0,
                "Duration": 0,
                "Entity_Density": 0,
                "Market_Scope": 0,
                "Time_Proximity": 0,
                "Headline_Structure": 0,
                "Source_Recency": 0
            }
        },
        {
            "time": "",
            "original_text": "沃森生物年报遭深交所11问 营收11亿应收账款近6亿 问询",
            "features": {
                "keywords": [
                    "沃森生物",
                    "年报",
                    "深交所",
                    "营收",
                    "应收账款",
                    "问询"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "沃森生物年报遭深交所11问 营收11亿应收账款近6亿 问询",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "国产“沛儿”获批上市，将与辉瑞争夺市场",
            "features": {
                "keywords": [
                    "沃森生物",
                    "沛儿",
                    "获批上市",
                    "辉瑞",
                    "市场竞争"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国产“沛儿”获批上市，将与辉瑞争夺市场",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "沃森生物年报收深交所11问 销售收入与批签发量变动不一致遭质疑",
            "features": {
                "keywords": [
                    "沃森生物",
                    "年报",
                    "深交所",
                    "销售收入",
                    "批签发量",
                    "质疑"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "沃森生物年报收深交所11问 销售收入与批签发量变动不一致遭质疑",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]